| [1] |
Mekkawy AH, Pourgholami MH, Morris DL. Involvement of urokinase-type plasminogen activator system in cancer: an overview[J]. Med Res Rev, 2014, 34(5): 918-56.
|
| [2] |
Tjwa M, Sidenius N, Moura R, et al. Membrane-anchored uPAR regulates the proliferation, marrow pool size, engraftment, and mobilization of mouse hematopoietic stem/progenitor cells[J]. J Clin Invest, 2009, 119(4): 1008-18.
|
| [3] |
Ahn SB, Mohamedali A, Anand S, et al. Characterization of the interaction between heterodimeric αvβ6 integrin and urokinase plasminogen activator receptor (uPAR) using functional proteomics[J]. J Proteome Res, 2014, 13(12): 5956-64.
|
| [4] |
Croucher DR, Saunders DN, Lobov S, et al. Revisiting the biological roles of PAI2 (SERPINB2) in cancer[J]. Nat Rev Cancer, 2008, 8(7): 535-45.
|
| [5] |
Zhang AH, Li XL, Sun DC, et al. Clinical research on the changes of plasma TFPI and uPA system in malignant tumor[J]. The Chin- German J Clin Oncol, 2004, 3(2): 78-80.
|
| [6] |
Zhu LD, Kong PY, Zhang X, et al. A preliminary investigation: screening of serum protein markers by protein microarray technology in acute myeloid leukemia[J]. Zhongguo Shu Xue Za Zhe, 2013, 26(3): 110-5. [朱丽丹, 孔佩艳, 张曦, 等. 蛋白芯片用 于筛选急性髓系白血病患者血清标志物的初步研究[J]. 中国输 血杂志, 2013, 26(3): 110-5]
|
| [7] |
Scherrer A, Wohlwend A, Kruithof EK, et al. Plasminogen activation in human acute leukaemias[J]. Br J Haematol, 1999, 10 5(4): 920-7.
|
| [8] |
Li Q, Li M, Wu YH, et al. Detection of cytokine expression patterns in the peripheral blood of patients with acute leukemia by antibody microarray analysis[J]. J Huazhong Univ Sci Technolog Medl Sci, 2014, 34(2): 176-80.
|
| [9] |
Paschos KA, Canovas D, Bird NC. Enzymatic function of multiple origins regulates the progression of colorectal cancer and the development of metastases[J]. Hippokratia, 2009, 13(1): 23-31.
|
| [10] |
Graf M, Reif S, Hecht K, et al. High expression of urokinase plasminogen activator receptor (UPA-R) in acute myeloid leukemia (AML) is associated with worse prognosis[J]. Amer J Hematol, 2005, 79(1): 26-35.
|
| [11] |
Atfy M, Eissa M, Salah HE, et al. Role of urokinase plasminogen activator receptor (CD87) as a prognostic marker in acute myeloid leukemia[J]. Med Oncol, 2012, 29(3): 2063-9.
|
| [12] |
Plesa C, Chelghoum Y, Plesa A, et al. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia:a single institution experience[J]. Cancer, 2008, 112(3): 57 2-80.
|
| [13] |
Mason KD, Juneja SK, Szer J. The immunophenotype of acute myeloid leukemia: is there a relationship with prognosis?[J]. Blood Rev, 2006, 20(2): 71-82.
|
| [14] |
Aref S, El-Sherbiny M, Mabed M, et al. Urokinase plasminogen activator receptor and soluble matrix metalloproteinase-9 in acute myeloid leukemia patients: a possible relation to disease invasion[J]. Hematology, 2003, 8(6): 385-91.
|
| [15] |
Haastrup E, Andersen J, Ostrowski SR, et al. Soluble urokinase plasminogen activator receptor during allogeneic stem cell transplantation[J]. Scand J Immunol, 2011, 73(4): 325-9.
|
| [16] |
Kaya S, Köksal I, Mente?e A, et al. The significance of serum urokinase plasminogen activation receptor (suPAR) in the diagnosis and follow-up of febrile neutropenic patients with hematologic malignancies[J]. Int J Infect Dis, 2013, 17(11): e1056-9.
|
| [17] |
Yilmaz M, Dagdas S, Aki SZ, et al. The relation between plasminogen activator inhibitor activity and disease activation in acute myeloblastic leukaemia patients[J]. Clin Lab Haematol, 20 06, 28(5): 313-6.
|
| [18] |
Zhang H, Zheng HY. Epigenetic mechanism of RUNX1 in pathogenesis of leukemia-Review[J]. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2010, 18(2):525-30. [张寒, 郑胡镛. RUNX1表观遗 传机制在白血病发生中的作用研究进展[J]. 中国实验血液学杂 志, 2010, 18(2): 525-30. ]
|
| [19] |
Kopf E, Miskin R. A RUNX/AML-binding motif residing in a novel 13‐bp DNA palindrome may determine the expression of the proximal promoter of the human uPA gene[J]. J Throm Haemost, 2005, 3(9): 2057-64.
|
| [20] |
Liu YH, Wang ZY, Zhang W, et al. Clinical study on the fibrinolytic activity in patients with acute promyelocytic leukemia[J]. Zhonghua Xue Ye Xue Za Zhi, 2009, 30(3): 145-9.
|
| [21] |
Dar A, Schajnovitz A, Lapid K, et al. Rapid mobilization of hematopoietic progenitors by AMD3100 and catecholamines is mediated by CXCR4-dependent SDF-1 release from bone marrow stromal cells[J]. Leukemia, 2011, 25(8): 1286-96.
|
| [22] |
Devy L, Hollender P, Munaut C, et al. Matrix and serine protease expression during leukemic cell differentiation induced by aclacinomycin and all-trans-retinoic acid[J]. Biochem Pharmacol, 20 02, 63(2): 179-89.
|
| [23] |
Ramage JG, Vallera DA, Black JH, et al. The diphtheria toxin/ urokinase fusion protein (DTAT) is selectively toxic to CD87 expressing leukemic cells[J]. Leuk Res, 2003, 27(1): 79-84.
|
| [24] |
Abi-HabibRJ, Liu SH, Bugge TH, et al. A urokinase-activated recombinant diphtheria toxin targeting the granulocytemacrophage colony-stimulating factor receptor is selectively cytotoxic to human acute myeloid leukemia blasts[J]. Blood, 20 04, 104(7): 2143-8.
|
| [25] |
Devy J, Ouchani F, Oudot C, et al. The anti-invasive activity of synthetic alkaloid ethoxyfagaronine on L1210 leukemia cells is mediated by down-regulation of plasminogen activators and MT1- MMP expression and activity[J]. Invest New Drugs, 2011, 29(5): 73 0-41.
|
下载:
